E Fund Management Co. Ltd. Has $184,000 Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

E Fund Management Co. Ltd. decreased its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 6.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,125 shares of the biopharmaceutical company’s stock after selling 660 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Celldex Therapeutics were worth $184,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in CLDX. Vanguard Group Inc. raised its position in shares of Celldex Therapeutics by 0.4% in the first quarter. Vanguard Group Inc. now owns 3,898,435 shares of the biopharmaceutical company’s stock valued at $70,757,000 after buying an additional 16,440 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Celldex Therapeutics by 23.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company’s stock valued at $89,890,000 after buying an additional 676,771 shares in the last quarter. Point72 Asset Management L.P. raised its position in shares of Celldex Therapeutics by 50.8% in the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company’s stock valued at $63,579,000 after buying an additional 847,264 shares in the last quarter. Deep Track Capital LP acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at approximately $38,919,000. Finally, Rock Springs Capital Management LP raised its position in shares of Celldex Therapeutics by 10.7% in the fourth quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company’s stock valued at $30,885,000 after buying an additional 118,404 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have recently weighed in on CLDX. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Celldex Therapeutics in a research report on Friday, June 13th. Canaccord Genuity Group began coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They issued a “buy” rating and a $64.00 price target for the company. UBS Group dropped their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group lowered their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating for the company in a research report on Friday, May 9th. Finally, Morgan Stanley lowered their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Friday, May 9th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.75.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $25.50 on Friday. The firm’s fifty day moving average price is $21.92 and its two-hundred day moving average price is $20.72. The stock has a market cap of $1.69 billion, a PE ratio of -8.47 and a beta of 1.22. Celldex Therapeutics, Inc. has a fifty-two week low of $14.40 and a fifty-two week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.01. The firm had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $1.13 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. As a group, sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.